Fennec Pharmaceuticals Inc. (FENC)
Market Cap | 167.58M |
Revenue (ttm) | 49.35M |
Net Income (ttm) | -1.13M |
Shares Out | 27.43M |
EPS (ttm) | -0.04 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 48,814 |
Open | 6.11 |
Previous Close | 6.14 |
Day's Range | 5.92 - 6.19 |
52-Week Range | 3.96 - 11.92 |
Beta | 0.35 |
Analysts | Strong Buy |
Price Target | 14.00 (+129.13%) |
Earnings Date | Nov 7, 2024 |
About FENC
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is ba... [Read more]
Financial Performance
In 2023, Fennec Pharmaceuticals's revenue was $21.25 million, an increase of 1284.50% compared to the previous year's $1.54 million. Losses were -$16.05 million, -32.34% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for FENC stock is "Strong Buy." The 12-month stock price forecast is $14.0, which is an increase of 129.13% from the latest price.
News
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa...
Fennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2024 Earnings Conference Call November 9, 2024 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Off...
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to ...
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp...
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth
~ Pierre S. Sayad, PhD, M.S.
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp...
Fennec Pharmaceuticals Inc. (FENC) Q2 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Robert Andrade - CFO Jeffrey Hackman - CEO and Board Member Conference Call ...
Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $...
Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024
Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference
Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment t...
Fennec Pharmaceuticals Announces Management Change
RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian H...
Fennec Announces Results of Annual Meeting
RESEARCH TRIANGLE PARK, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy cir...
Fennec Pharmaceuticals Inc. (FENC) Q1 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Rosty Raykov - Chief Executive Officer and Director Robert Andrade - Chief Fina...
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa...
Fennec Pharmaceuticals Inc. (FENC) Q4 2023 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (FENC) Q4 2023 Earnings Call Transcript
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Com...
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI® , the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-in...
Fennec Pharmaceuticals: Great Sales Progress - Not Yet Reflected In Stock Price
Fennec released sales guidance for Q4 2023, exceeded analyst expectations. A pending EU launch of PEDMARK® provides a near term opportunity for the Company to finalize an EU partnership. Revenue growt...
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH TRIANGLE ...
FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the U.S....
Fennec Announces Incremental $5 Million Investment from Petrichor
~ Supports Strategic Discussions and Global Launch Activities ~ ~ Extends Access to Additional Undrawn Capital As Needed During Global PEDMARK® Rollout ~ ~ Facilitates Market Expansion into the Adoles...
Fennec Pharmaceuticals Expands Possible TAM Significantly
Fennec Pharmaceuticals is a commercial-stage biotech company with a single drug, PEDMARK®, which is FDA-approved to reduce the risk of hearing loss in pediatric cancer patients. The company faced chal...
Fennec Pharmaceuticals Inc. (FENC) Q3 2023 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2023 Earnings Conference Call November 6, 2023 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Rosty Raykov - Chief Executive Off...